Neteera raises an additional $6.7M Series B Extension

Neteera Technologies Ltd., an Israeli-based startup disrupting the contactless patient monitoring market, today announced the successful closing of a ~$6,7M Series B extension. The round was led by Aescuvest, a renowned healthcare investment firm, alongside Foxconn Technology Co., Ltd. (FTC), an associate of Hon Hai Precision Industry Co., Ltd., the largest electronics manufacturer globally.

The funds of this extension round will be used to expedite production, meet the increasing demand for Neteera’s platform, and to recruit more installation and deployment personnel. This significant step will allow Neteera to further solidify its leadership in the contactless patient monitoring market.

Partnering with Foxconn Technology Group, the world’s leading company and powerhouse in the electronics manufacturing market, will further boost Neteera’s international growth. A cooperation to produce Neteera’s products is already under way, with further business and technology collaborations in the pipeline.

“Neteera is an excellent medical equipment development company. We are delighted to participate in Neteera’s current round of funding and to become their manufacturing partner, providing strong support for the mass production of their products,” said William Hung, Chief Investment Officer at FTC.

In the face of challenging market conditions and VC funding slowdowns, Neteera has not only persevered but thrived. The startup’s big pull is its proven product-market-fit for a globally applicable problem, coupled with essential regulatory approvals, such as the FDA stamp.

Neteera successfully tackles a problem that we are all prone to. Our ageing populations deserve professional, humane care. Technological solutions such as Neteera’s platform are a suitable answer to combat the problems of our healthcare systems,” said Sebastian Gührs, Partner & Head of Investment at Aescuvest.

Founded in 2015, Neteera quickly gained recognition for its FDA-cleared remote patient monitoring platform, designed to enable continuous monitoring of patients’ biomarkers without the need for contact or patient involvement. The platform is improving patient care and operator efficiencies all over the globe.

Outside of raising money, Neteera has been working on expanding access to its contactless patient monitoring platform. In 2023, the company began selling its solution to a large number of long-term care facilities in the US and has a significant pipeline of ordered products that are currently being deployed.

We are proud to partner with such a renowned company as Foxconn to further expand our offering,” said Isaac Litman, CEO of Neteera. “This funding and cooperation will expedite our solution production and deployment, opening doors and allowing us to get one step closer to achieving our mission: saving life, improving patient care while reducing the burden on clinical staff.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”